Product Details

Uniprot No.

Target Names

Alternative Names

Protein arginine N-methyltransferase 5 (EC 2.1.1.320) (72 kDa ICln-binding protein) (Histone-arginine N-methyltransferase PRMT5) (Jak-binding protein 1) (Shk1 kinase-binding protein 1 homolog) (SKB1 homolog) (SKB1Hs) [Cleaved into: Protein arginine N-methyltransferase 5, N-terminally processed], PRMT5, HRMT1L5 IBP72 JBP1 SKB1

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human PRMT5

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

2H4

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, IHC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

PRMT5 (protein arginine N-methyltransferase 5) serves as a critical epigenetic regulator that catalyzes the symmetric dimethylation of arginine residues on histones and non-histone substrates. This enzymatic activity influences diverse cellular processes including transcriptional regulation, RNA splicing, and cell cycle progression, making PRMT5 a compelling target in cancer biology and epigenetic research. Dysregulation of PRMT5 has been implicated in multiple malignancies, positioning it as both a biomarker of interest and a potential therapeutic target.

This recombinant monoclonal antibody, generated against a synthetic peptide derived from human PRMT5, offers the reproducibility and sequence-defined consistency that demanding experimental workflows require. As a recombinant clone produced in rabbit, it eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations, ensuring your results remain comparable across experiments.

Validation studies demonstrate robust performance across multiple applications. In western blot analysis, the antibody detects a band at the expected 73 kDa molecular weight across a diverse panel of human cell lines including Raji, HeLa, HL60, Jurkat, and A549, confirming reliable detection in both hematological and solid tumor models. The antibody performs effectively at dilutions ranging from 1:500 to 1:5000 for western blotting. Immunohistochemistry validation in paraffin-embedded human prostate cancer tissue at 1:100 dilution reveals clear staining following citrate buffer antigen retrieval, demonstrating suitability for archival tissue analysis.

Whether investigating PRMT5's role in chromatin remodeling, exploring its function in oncogenic signaling pathways, or characterizing expression patterns in disease tissues, this antibody provides a dependable tool for epigenetics and nuclear signaling research.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Methylates SUPT5H and may regulate its transcriptional elongation properties. Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. Methylates histone H2A and H4 'Arg-3' during germ cell development. Methylates histone H3 'Arg-8', which may repress transcription. Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage. Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation. Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity. Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation. Methylates HOXA9. Methylates and regulates SRGAP2 which is involved in cell migration and differentiation. Acts as a transcriptional corepressor in CRY1-mediated repression of the core circadian component PER1 by regulating the H4R3 dimethylation at the PER1 promoter. Methylates GM130/GOLGA2, regulating Golgi ribbon formation. Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner. Symmetrically methylates POLR2A, a modification that allows the recruitment to POLR2A of proteins including SMN1/SMN2 and SETX. This is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. Along with LYAR, binds the promoter of gamma-globin HBG1/HBG2 and represses its expression. Symmetrically methylates NCL. Methylates TP53; methylation might possibly affect TP53 target gene specificity. Involved in spliceosome maturation and mRNA splicing in prophase I spermatocytes through the catalysis of the symmetrical arginine dimethylation of SNRPB (small nuclear ribonucleoprotein-associated protein) and the interaction with tudor domain-containing protein TDRD6.

Gene References into Functions

Expression of PRMT5 was significantly increased in human gastric cancer (GC) tissues compared with normal gastric mucosa. Multiple evidences suggested that PRMT5 repressed transcription of tumor suppressor IRX1 via recruitment of DNMT3A on promoter. PMID: 29802960
PRMT5 may play a role from early oncogenesis through to the progression of oral squamous cell carcinoma , particularly in the aggressive mode of stromal invasion PMID: 29603824
he phosphorylation of the MP inhibitory MYPT1(T850) and the regulatory PRMT5(T80) residues as well as the symmetric dimethylation of H2A/4 were elevated in human hepatocellular carcinoma and in other types of cancers. PMID: 28074910
The polymerase-associated factor complex regulates Prmt5 to facilitate leukemic progression and is a potential therapeutic target for acute myeloid leukemias. PMID: 28945229
our results indicated that PRMT5 overexpression in hepatocellular carcinoma (HCC)and colon cancer cells contributed to their acquisition of aggressive characteristics, such as invasiveness, thus presenting a promising therapeutic target for the treatment of these diseases PMID: 29749478
PRMT5 as a key in vitro and in vivo regulator of breast cancer stem cells proliferation. PRMT5 epigenetically regulates FOXP1. PMID: 29262329
Protein arginine methyltransferase 5 (PRMT5) was identified to be responsible for Eno-1 methylation. Overexpression of PRMT5 and caveolin-1 enhanced levels of membrane-bound extracellular Eno-1 and, conversely, pharmacological inhibition of PRMT5 attenuated Eno-1 cell-surface localization. PMID: 29501774
A 3.7 A structure of PRMT5, solved in complex with regulatory binding subunit MEP50 (methylosome associated protein 50, WDR77, p44), by single particle (SP) cryo-Electron Microscopy (cryo-EM) using micrographs of particles that are visibly crowded and aggregated. The catalytic PRMT5 subunits form a core tetramer and the MEP50 subunits are arranged peripherally in complex with the PRMT5 N-terminal domain. PMID: 29518110
These kinetic studies suggest a biochemical explanation for the interplay between PRMT5- and PRMT7-mediated methylation of the same substrate at different residues and also suggest a general model for regulation of PRMTs. PMID: 28874563
Data indicate the significant potential of PRMT5 as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). PMID: 28591716
PRMT5 inhibited the interaction between CDK4 and CDKN2A and then activated the CDK4-RB-E2F pathway in hepatocellular carcinoma cells under glucose induction. PMID: 27708221
Data suggest that the protein arginine methyltransferase 5 (PRMT5)-E2F1 transcription factor (E2F-1) pathway may act as a common target for exogenous lectins including Anguilla japonica lectin 1 (AJL1), and the cellular response to exogenous AJL1 may suggest a novel agent for cancer gene therapy. PMID: 26990556
These results could be helpful in discovering new potent and specific inhibitors of PRMT5, as well as in designing mutant residue assay to modulate the catalytic activity of PRMT5. PMID: 29154828
PRMT1 inhibition prevents gastric cancer progression by downregulating eIF4E and targeting type II PRMT5. PMID: 28987382
Data indicate that ZNF326 is an interaction partner and substrate of the PRMT5/WDR77 complex. PMID: 28977470
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. PMID: 27183006
SFN treatment of tumors results in reduced MEP50 level and H4R3me2s formation, confirming that that SFN impacts this complex in vivo. These studies suggest that the PRMT5/MEP50 is required for tumor growth and that reduced expression of this complex is a part of the mechanism of SFN suppression of tumor formation. PMID: 28854561
High nuclear PRMT5 expression is associated with oropharyngeal squamous cell carcinoma. PMID: 28107179
High PRMT5 expression is associated with prostate cancer. PMID: 27546619
Results provide evidence that PRMT5 and p44 regulate gene expression of growth and anti-growth factors to promote lung tumorigenesis. PMID: 27480244
PRMT5 regulates internal ribosome entry site-dependent translation via methylation of hnRNP A1. PMID: 28115626
PRMT5 knockdown reduces growth, survival, and colony formation of chronic myelogenous leukemia CD34+ cells. PMID: 27643437
Methylation of RUVBL1 by the arginine methyltransferase PRMT5 is required for homologous recombination-mediated double-strand break repair by promoting TIP60-mediated histone H4K16 acetylation. PMID: 28238654
findings show that PRMT5 is an important modulator of CD4(+) T cell expansion; PRMT5 was transiently upregulated during maximal proliferation of mouse and human memory Th cells; data implicate PRMT5 in the regulation of adaptive memory Th cell responses PMID: 28087667
Results provide evidence that PRMT5 differentially regulates self-renewal, survival and proliferation of primary glioblastoma neurosphere cells (GBMNS) PMID: 27292259
PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes. PMID: 27860244
The C-terminal motif of PRMT5 is required for plasma membrane association, and loss of this switching capacity is not compatible with life. This signaling phenomenon was recently reported for the HPV E6 oncoprotein but has not yet been observed for mammalian proteins PMID: 28031468
our results indicate that PRMT5 may act as a putative oncogene in hepatocellular carcinoma PMID: 28101581
high expression of PRMT5 in primary and metastatic breast cancer lesions and indicated its function in cell proliferation, cell cycle progression, and apoptosis. PMID: 28381188
Study showed that PRMT5 mRNA levels were significantly higher in gastric cancer (GC) tissues and were independent of tumor depth, differentiation and lymph node metastasis. Findings indicate that PRMT5 acts as an oncogene in GC by enhancing the malignant phenotype of a cancer cell line. PMID: 27315569
PRMT5 as an ASK1-binding protein.PRMT5 mediates arginine methylation of ASK1. PMID: 26912789
methionine adenosyltransferase II alpha (MAT2A), and the arginine methyltransferase, PRMT5, as vulnerable enzymes in cells with MTAP deletion. PMID: 27068473
Our results indicate that PRMT5 is a marker of poor prognosis in NPC patients. PRMT5 promoted the radioresistance of NPC cells via targeting FGFR3, at least partly if not totally. PMID: 26708443
Data show that Omomyc protein co-localized with proto-oncogene protein c-myc (c-Myc), protein arginine methyltransferase 5 (PRMT5) and histone H4 H4R3me2s-enriched chromatin domains. PMID: 26563484
PRMT5 expression was upregulated during HTLV-1-mediated T-cell transformation. PMID: 26729154
Increased PRMT5 activity enhanced acute myeloid leukemia growth. PMID: 26536822
arginine residues within the third intracellular loop of the D2 dopamine receptor were methylated by protein arginine methyltransferase 5 (PRMT5) PMID: 26554819
high nuclear expression of Protein arginine methyltransferase-5 is a potentially useful marker for estimating submucosal invasion of early colorectal carcinomas in endoscopically resected specimens PMID: 26248553
Findings provide new evidence that PRMT5 plays an important role in CRC pathogenesis through epigenetically regulating arginine methylation of oncogenes such as eIF4E and FGFR3. PMID: 26078354
PRMT5-induced methylation prevented phosphorylation of SREBP1a on S430 by GSK3beta PMID: 26759235
PRMT5 plays an important role in human hepatocellular carcinoma growth via the downregulation of beta-catenin PMID: 26541651
PRMT5 gene is silencing gene expression by histone arginine methylation in keratinocytes. PMID: 26763441
PRMT5 co-localizes with RASSF1A on stabilized microtubules.RASSF1A promotes the translocation of cytosolic PRMT5 to microtubules. PMID: 26482848
UHRF1 could form a complex with PRMT5 to contribute to the endometrial carcinogenesis. PMID: 26597461
these findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" genomic alteration. PMID: 26912360
methylthioadenosine accumulation in 5-methylthioadenosine phosphorylase-deleted cancers creates a hypomorphic PRMT5 state that is selectively sensitized toward further PRMT5 inhibition. PMID: 26912361
PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease. PMID: 25927346
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers PMID: 25582697
The novel PRMT5S likely contributes to the observed diverse effects of PRMT5 in cells. PMID: 26151339
These studies implicate PRMT5 in a novel mode of MYCN post-translational regulation. PMID: 25475372

Hide All

Subcellular Location

Cytoplasm. Nucleus. Chromosome. Golgi apparatus.

Protein Families

Class I-like SAM-binding methyltransferase superfamily, Protein arginine N-methyltransferase family

Tissue Specificity

Ubiquitous.

Database Links

HGNC: 10894

OMIM: 604045

KEGG: hsa:10419

STRING: 9606.ENSP00000319169

UniGene: Hs.367854

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA176962A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: Raji whole cell lysate, Hela whole cell lysate, HL60 whole cell lysate, Jurkat whole cell lysate, A549 whole cell lysate All lanes: PRMT5 antibody at 1:2000 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 73, 72, 54, 68, 67 kDa Observed band size: 73 kDa IHC image of CSB-RA176962A0HU diluted at 1:100 and staining in paraffin-embedded human prostate cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions?	Leave a Message or Start an on-line Chat

PRMT5 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background